Diagonal Therapeutics raised $125 million to advance DIAG723, designed to restore ALK1 signaling in hereditary hemorrhagic telangiectasia (HHT), addressing the root cause of abnormal blood vessel formation and chronic anemia.
Diagonal Therapeutics raised $125 million to advance DIAG723, designed to restore ALK1 signaling in hereditary hemorrhagic telangiectasia (HHT), addressing the root cause of abnormal blood vessel formation and chronic anemia.